Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.
Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD
https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
@CombatCancer #HIPEC Don't forget to register to join Combat and Dr Alvaro-Arjona-Sanchez later today to find out more.
https://www.urotoday.com/conference-highlights/aua-2020/aua-2020-bladder-cancer/122466-aua-2020-bcg-vs-chemohyperthermia-with-mitomycin-c-for-high-risk-non-muscle-invasive-bladder-carcinoma-preliminary-results-of-hivec-hr-randomized-clinical-trial.html via @urotoday
Many thanks @urotoday for covering our trial data https://twitter.com/urotoday/status/1276923364402225152
#BCG vs chemohyperthermia with mitomycin C for high-risk #NMIBC. Preliminary results of HIVEC-HR randomized clinical trial presented by @DrFelixGuerrero @Urologia12. #AUAlive written coverage by @zklaassen_md @GACancerCenter on UroToday > https://bit.ly/384fw6I @AmerUrological
#HIPEC #Laparoscopic #SurgicalOncology @CombatCancer Join Combat and Consultant Surgeon Dr Alvaro-Arjona-Sanchez to find out more about Laparoscopic HIPEC experience and results. Register for online event https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
Don't forget to register for tomorrow's clinical discussion on HIVEC-R, look forward to seeing you and sharing this data that was selected for AUA20 #HIVEC
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
@Yormigjgv @DrFelixGuerrero @smumexico @UroTratamiento @Urologia12 Webinar:
Inscripción
ID de reunión: 915 9289 1390
Welcome! You are invited to join a webinar: Evaluación Clínica de Quimioterapia Térmica para Cáncer de Vejiga: Ponencia AUA 2020. After registering, you will receive a confirmation email about joining the webinar.
Ponente: Dr. Felix Guerrero Títular de la Unidad de Uroncología del Hospital Universitario 12 de Octubre, Madrid, España. Jefe la Unidad de Cáncer...
zoom.us
@CombatCancer #HIVEC Neo-Adjuvant HIVEC shows over 60% complete response and better RFS in preliminary trial result. Abstract accepted for AUA20, follow link to see full abstract https://bit.ly/2W2bA1Q
Its #BladderCancerAwarenessMonth If you have any of the symptoms, blood in your urine, frequency or difficulty and pain during urination please pleas ego see your GP. It could save your life. Check out @CombatCancer for further details
I told a patient she had bladder cancer this morning, and she said to me that she would be clapping tonight ♥️🇬🇧😷♥️😷
El @DrFelixGuerrero presenta los resultados del ensayo HIVEC-HR, comunicado recientemente en #AUA20 @AmerUrological, en el webinar organizado por @CombatCancer #HIVEC #bladdercancer
➡ Más información: https://bit.ly/2A0qGwe
¡Sigue el webinar online 👉 https://bit.ly/3cV7HBV!
If you're free later today, 6pm Madrid time, please join us #HIVEC for presentation Q&A on HIVEC HR trial
https://hivec-hr.eventbrite.co.uk #HIVEC #AUA20
Please join Combat and Dr Guerrero-Ramos for a presentation of the HIVEC HR trial with live Q&A
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author
